Cosmos Health projects $12M+ revenue from U.S. expansion

Cosmos Health Inc. (NASDAQ: COSM) announced its U.S. market expansion is underway with NOOR Collagen projected to generate more than $12 million in annualized revenue. The company expects gross margins of approximately 75% from its Sky Premium Life U.S. operations.

The healthcare company entered into a letter of intent on March 6 to acquire a pharmacy distribution network generating approximately $11.5 million in annual gross revenue in the Greek market. The network serves pharmacy customers with pharmaceutical and para-pharmaceutical products.

Cosmos Health holds non-core assets including real estate with an estimated fair market value of approximately $15 million and $3.1 million in digital assets. The company is evaluating potential monetization of these assets, which collectively have an estimated fair market value exceeding $18 million.

Zacks Small-Cap Research initiated coverage on the company with a $4.50 per share valuation in a report published January 13. The research highlighted the company's diversified revenue base and vertically integrated operations.

The company's C-Scrub product expanded retail presence at Tesco and Superdrug in the United Kingdom. All NOOR Sky Premium Life products sold in the U.S. are manufactured locally in GMP-certified, FDA-registered facilities.

Cosmos Health appointed Dr. Dimitrios Iliopoulos, an expert in AI-driven drug discovery, to its Advisory Board. The company plans to issue updated guidance following the release of its fourth quarter and full-year 2025 financial results.

"Given current valuation levels, we are also evaluating capital allocation alternatives, including share repurchases," CEO Greg Siokas stated in the press release.

You May Also Be Interested In

• Sysco adds two directors, targets AI-driven cost savings of $100M
• NextTrip launches B2B travel platform for advisors and agencies
• Circle8 Group posts record $569.7M first-half revenue, reports net loss